Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Arcadia Biosciences reported a net loss of $8.9 million for the nine months ended September 30, 2026, compared to a $1.0 million loss in the prior year, primarily driven by valuation losses on financing activities. Total revenues increased to $4.16 million for the nine-month period, while the company strengthened its cash position to $2.84 million through various inducement offers and PIPE financing.
Obsidian Therapeutics is a clinical-stage biopharmaceutical company focused on developing amsoki-cel (formerly OBX-115). As of November 9, 2026, the company had 61,774,046 shares of common stock outstanding and continues to incur significant financial losses to fund its research and development programs.
Castle Biosciences Chief Commercial Officer Tobin W. Juvenal Sells $207K of Stock
Tobin W. Juvenal, Chief Commercial Officer, sold 6,116 shares of Castle Biosciences Inc at $32.67 to $35.04 a share (average $33.77) in 2 transactions, worth $207K in total between Nov 9, 2026 and Nov 11, 2026. Shares held after the trade: 32,737 (-8.0%).
Silexion Therapeutics Corp effected a 1-for-24 reverse share split of its ordinary shares effective after the close of trading on November 10, 2026. In connection with the split, the company adjusted its outstanding warrants, increasing the exercise price 24-fold to $372,600.00 per post-split share and reducing the number of shares issuable per warrant to 1/24th of a share.
Option Care Health Insider R. Carter Pate Sells $205K of Stock
R. Carter Pate sold 6,492 shares of Option Care Health, Inc. at $31.65 a share, worth $205K in total between Nov 10, 2026 and Nov 11, 2026. Shares held after the trade: 14,128 (-2.8%).
Serina Therapeutics reported third quarter 2026 financial results and provided a clinical update on its SER-252 program for Parkinson's disease. The company has advanced to Cohort 2 of its registrational study following a positive safety review, with topline single-ascending-dose data expected in the first half of 2027.
“We are excited about the achievement of important clinical milestones for SER-252 in Parkinson's disease, advancing from the initial evaluation of our lowest-dose cohort into the next stage of dose escalation. Importantly, the blinded pharmacokinetic observations from Cohort 1 showed the sustained drug exposure SER-252 was designed to achieve, and the independent Safety Monitoring Committee recommended proceeding with continued development.”
Eastman Chemical $300M Debt Financing with Computershare Trust Company, National Association
Eastman Chemical Company issued $300 million in 5.500% Notes due 2030 in a public offering. The notes are general unsecured obligations maturing on February 25, 2030, with interest payable semi-annually. Proceeds are intended for general corporate purposes, which may include the repayment of existing indebtedness.
Advanced Flower Capital Insider Leonard M. Tannenbaum Buys $97.8K of Stock
Leonard M. Tannenbaum bought 29,108 shares of Advanced Flower Capital Inc. at $3.22 to $3.42 a share (average $3.36) in 2 transactions, worth $97.8K in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 7,157,222 (+0.3%).
SoundThinking reported third quarter 2026 financial results with revenue of $25.0 million, which remained flat year-over-year. The company reported a GAAP net loss of $8.5 million, widened from a $2.0 million loss in the prior year, largely due to costs associated with its pending acquisition by Transom Capital Group. The company expects to close the Transom Transaction, which values the company at up to $159 million including contingent value rights, in the fourth quarter of 2026.
Motorola Solutions SVP, COS to the Chairman & CEO Cynthia Yazdi Sells $2.22M of Stock
Cynthia Yazdi, SVP, COS to the Chairman & CEO, sold 4,227 shares of Motorola Solutions, Inc. at $524.59 to $524.78 a share (average $524.60) in 3 transactions, worth $2.22M in total on Nov 9, 2026. Shares held after the trade: 5,417 (-42.5%).
Apollo Commercial Real Estate Finance Liquidating Trust Divestiture
Apollo Commercial Real Estate Finance, Inc. (ARI) completed its plan of liquidation by transferring all remaining assets and liabilities to the Apollo Commercial Real Estate Finance Liquidating Trust. ARI stockholders received non-transferable units of beneficial interest in the trust on a one-for-one basis, and ARI's common stock has been cancelled and deregistered from the SEC.
Planet 13 Holdings reported a net loss of $20.0 million for the nine months ended September 30, 2026, an improvement from the $59.3 million loss in the prior year period. The company successfully exited all California operations during the quarter and is monitoring the impact of the U.S. Department of Justice's move to reclassify medical marijuana to Schedule III, which may alleviate Section 280E tax burdens.
Heartflow, Inc. reported a total asset base of $355.3 million as of September 30, 2026, with a significant accumulated deficit of $1.14 billion. The company remains focused on its Heartflow FFRCT and Plaque Analysis products while maintaining a liquid position of approximately $167.7 million in cash and short-term investments.
Serina Therapeutics reported a net loss of $21.2 million for the nine months ended September 30, 2026, as it continues to invest in research and development. The company significantly strengthened its balance sheet during the period, increasing cash and cash equivalents to $19.4 million through private placements and equity facilities.
For the nine months ended September 30, 2026, Antares Private Credit Fund reported total investment income of $114.9 million and net investment income of $52.7 million. Net assets increased by $39.5 million from operations, though the fund experienced a net change in unrealized depreciation of $12.0 million during the period.
Once Upon a Farm reported Q3 2026 net sales of $89.1 million, a 35% increase year-over-year driven by 32% volume growth. The company narrowed its net loss to $3.8 million from $11.3 million in the prior year, though Adjusted EBITDA shifted to a $1.0 million loss due to lower gross margins from trade investments and product mix.
Term
Q3 2026
“Third quarter results demonstrated our ability to increase brand awareness and household penetration, deepen and expand retail reach, and deliver value added innovation. As more families consume our products in greater frequency, alongside disciplined investment and execution, we are on course to build the first truly baby through kid brand, with meaningful operating leverage and structurally higher margins as we scale.”
John Foraker, CEO and co-founder of Once Upon a Farm
“We are building one of the most compelling, durable growth platforms in food with increasing household penetration, strong consumer loyalty, attractive retail productivity, and significant opportunities to expand our reach in new categories relevant to our consumers.”
John Foraker, CEO and co-founder of Once Upon a Farm
Invesco Galaxy Solana ETF Debt Financing Update with Coinbase Credit, Inc.
The Invesco Galaxy Solana ETF entered into a Master Loan Agreement with Coinbase Credit, Inc. for a multiple-draw secured digital asset borrowing facility. The facility allows the Trust to borrow digital assets or cash, secured by a first-priority security interest in collateral held at Coinbase, to facilitate the Trust's SOL staking activities. Additionally, the Trust entered into a digital assets custody agreement with The Bank of New York Mellon to maintain segregated custody accounts for its SOL holdings.
Sensus Healthcare reported Q3 2026 revenue of $6.0 million, a 13% decrease year-over-year due to a shift in product mix and the absence of sales to a historically large customer. Despite lower revenue, gross margin improved significantly to 55% from 39.1% in the prior year, and the company reached a milestone of 1,000 SRT systems placed.
Term
Q3 2026
“Our third quarter results reflect continued progress in building a broader, more diversified customer base and advancing our business toward sustainable profitability.”
Joseph Sardano, Chairman and Chief Executive Officer
“Our focus is on converting these opportunities into sales, increasing utilization and building a more diversified, sustainably profitable business.”
Joseph Sardano, Chairman and Chief Executive Officer
Kodiak Sciences Inc. reported a net loss of $190.0 million for the first nine months of 2026, compared to $173.2 million in the prior year period, driven primarily by increased research and development expenses. The company's cash position decreased significantly to $88.7 million as of September 30, 2026, and management indicated a need to raise additional capital to maintain operations and continue its clinical development programs.
LCI Industries announced that its Board of Directors has approved a regular quarterly cash dividend of $1.15 per share of common stock. The dividend is scheduled to be paid on December 11, 2026, to stockholders of record as of November 27, 2026.
Teva Pharmaceutical Industries See "Remarks" Mark Sabag Sells $1.97M of Stock
Mark Sabag, See "Remarks", sold 44,710 shares of Teva Pharmaceutical Industries Ltd at $44.14 a share, worth $1.97M in total on Nov 12, 2026. Shares held after the trade: 80,760 (-35.6%).
Streamex Corp. reported a significant increase in net loss to $78.7 million for the nine months ended September 30, 2026, compared to $38.8 million in the prior year, primarily driven by a surge in general and administrative expenses. The company transitioned its focus toward gold-leasing activities and digital assets, while successfully extinguishing $38 million in convertible debentures during the period.
GrabAGun Digital Holdings Inc. reported a net loss of $6.69 million for the nine months ended September 30, 2026, compared to a loss of $2.92 million in the prior year period, despite a 5.3% increase in net revenues to $70.38 million. The company's cash position decreased to $96.03 million from $110.40 million at year-end 2025, primarily due to increased capital expenditures and stock repurchases.
For the nine months ended September 30, 2026, Remora Capital Corp reported total investment income of $18.0 million and net investment income of $10.9 million. The company's Net Asset Value (NAV) per common share decreased from $9.98 at the end of 2025 to $9.75, primarily driven by $4.6 million in net unrealized depreciation on investments.
Prime Medicine reported a net loss of $130.3 million for the nine months ended September 30, 2026, an improvement from the $155.1 million loss in the prior year period. Total revenue increased to $6.2 million, primarily driven by collaboration revenue from related parties, while total stockholders' equity significantly declined from $120.9 million to $8.4 million during the first nine months of 2026.
Bolt Biotherapeutics reported Q3 2026 financial results and provided a business update following its acquisition of Prana Therapies and a concurrent $120 million private placement. The company is shifting its primary focus to the INSPIRE-built pipeline, specifically the Phase 2 development of PRA-216 for inflammatory indications, with a cash runway extending into 2028.
“Completing the Prana acquisition marks an important transformation for Bolt. With a strong balance sheet, an advanced clinical program and a differentiated platform, we believe we are well positioned to execute against the important milestones ahead.”
Willie Quinn, President and Chief Executive Officer
“The transaction and financing provide us with the capital and public-company foundation to advance PRA-216 and the broader INSPIRE pipeline through what we believe will be an exciting and highly data-rich period ahead.”
Parabilis Medicines, Inc. is a clinical-stage biotechnology company that remains pre-revenue and has incurred significant losses since inception. As of November 9, 2026, the company had approximately 125.3 million total shares outstanding and is focused on advancing its Helicon discovery platform and lead product candidate, zolucatetide.
Crescent Biopharma, Inc. is a clinical-stage biotechnology company focused on developing its lead program, CR-001, and other product candidates. The company has a limited operating history, has never generated revenue from product sales, and anticipates continued losses for the foreseeable future as it advances its clinical trials.
Universal Electronics Insider Eric Singer Sells $581K of Stock
Eric Singer sold 102,827 shares of Universal Electronics Inc at $5.51 to $5.67 a share (average $5.65) in 2 transactions, worth $581K in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 999,005 (-8.3%).
Rank One Computing M&A Deal with Zuccaro Technical Consulting LLC
Rank One Computing Corporation (ROC) filed this amendment to provide required audited and pro forma financial statements following its completed acquisition of Zuccaro Technical Consulting LLC (ZTC). The transaction, which closed on August 31, 2026, involved ROC acquiring all issued and outstanding membership interests of ZTC from ZTC Holdco, Inc.